ESMO

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. With interim results from a pivotal clinical trial of its lead PD-L1 checkpoint inhibitor incoming, biotech firm Checkpoint Therapeutics (...

Insider buying can be an encouraging signal for potential investors. Two health care companies saw notable insider buying this past week. A director at a specialty retailer added to his stake as well. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for...

The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence takes place, the gathering brings together pharma and biotech companies focused...

Biotech stocks put up a muted performance in the week ended Sept. 20 amid conference presentations and FDA approvals. Johnson & Johnson (NYSE: JNJ)'s Janssen unit received an FDA nod for label expansion for its prostate cancer drug Erleada, and Eisai Co., Ltd (OTC: ESALY)'s Lenvantinib...

The 2018 European Society for Medical Oncology Congress started Oct. 19 and runs through Oct. 23. Presentations at the congress over the weekend created flutter among stocks of large-cap pharma and biotech companies. Although at the outset most data looked promising, sifting through the nitty-...

The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference. Here’s a breakdown of the highlights. Five Prime Therapeutics Five Prime Therapeutics Inc (NASDAQ: FPRX) reported positive...

This year’s European Society for Medical Oncology conference was one that Bristol-Myers Squibb Co (NYSE: BMY) shareholders would like to forget. The primary focus for Bristol-Myers was the company’s failed CM-26 trial. Bristol-Myers shares are down 9.4 percent in early Monday...